A Phase 3 interventional study of Rufinamide (E2080) and Placebo in Lennox-Gastaut Syndrome, sponsored by Eisai Limited. Completed at 23 sites in Japan. Open to participants aged 4 Years to 30 Years. Per ClinicalTrials.gov, last updated 2018-01-24.
Sponsored by Eisai Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.
68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.
This study's enrollment of 66 is above the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.
Browse Lennox Gastaut Syndrome studies →Eisai Limited is the lead sponsor of 48 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rufinamide (E2080)
Drug: Placebo
Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period. Target maintenance dose: 15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)
Also known as: E2080
Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)
The sum of the frequencies of tonic seizures and atonic seizures was defined as the "tonic-atonic seizure frequency" and the percent change in tonic-atonic seizure frequency per 28 days was assessed. The percent change in tonic-atonic seizure frequency was calculated using the tonic-atonic seizure frequency per 28 days of the Observation Period as the baseline and the tonic-atonic seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in tonic - atonic seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\]. The frequency of epileptic seizures was recorded in the seizure diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner, and continued these practices throughout the study period.
Time frame: Baseline (28 day observational period) and End of Treatment (28 day treatment period)
Number of Participants Achieving a 50% Reduction in Tonic-atonic Seizure Frequency
50% Responder Rate in Tonic-Atonic Seizure Frequency was presented as the number of participants who achieved a 50% reduction in tonic-atonic seizure frequency.
Time frame: 12 weeks
Percent Change in Total Seizure Frequency (Per 28 Days)
Percent change in the total seizure frequency (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\].
Time frame: Baseline (28 day observational period) and End of Treatment (28 day treatment period)
Percentage Change in the Frequency of Seizures Other Than Tonic-atonic Seizures (Per 28 Days)
Percent change in the frequency of seizures other than tonic-atonic seizures (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\]. Seizures analyzed other than tonic-atonic seizures included: Partial seizure freq. (frequency), Absence seizure, Atyp. (atypical) absence seizure, Myoclonic seizure, Clonic seizure, Tonic seizure, Tonic-clonic seizure, Atonic seizure, \& Uncla. (unclassified) epileptic seizure. The frequency of epileptic seizures was recorded in the diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner.
Time frame: Baseline (28 day observational period) and End of Treatment (28 day treatment period)
Clinical Global Impression of Change (CGIC)
CGIC in participants with Lennox-Gastaut Syndrome (LGS) relative to placebo was presented as number of participants in each category at the final assessment (last observation carried forward \[LOCF\]) \& at Week 12 of the Treatment Period. The investigator assessed the CGIC by comparing the participants' condition during the 4 weeks immediately before the completion (or discontinuation \[d/c\]) of the Treatment Period to his/her condition during the 4-week Observation Period (for participants who d/c'd the study during the Treatment Period, the CGIC was assessed by comparing the participant's condition from the start to discontinuation of the study treatment to his/her condition during the 4-week Observation Period). The CGIC was assessed according to the following 7-grade scale based on the frequency \& severity of seizures, AEs, and overall conditions of daily life. Markedly improved, Improved, Slightly improved, Unchanged, Slightly worsened, Worsened, Markedly worsened.
Time frame: Up to Week 12 of the treatment period
| Milestone | Rufinamide (E2080) | Placebo |
|---|---|---|
| Started | 29 | 30 |
| Completed | 25 | 29 |
| Not completed | 4 | 1 |
| Withdrew: Adverse event | 4 | 1 |
The sum of the frequencies of tonic seizures and atonic seizures was defined as the "tonic-atonic seizure frequency" and the percent change in tonic-atonic seizure frequency per 28 days was assessed. The percent change in tonic-atonic seizure frequency was calculated using the tonic-atonic seizure frequency per 28 days of the Observation Period as the baseline and the tonic-atonic seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in tonic - atonic seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\]. The frequency of epileptic seizures was recorded in the seizure diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner, and continued these practices throughout the study period.
| Percent Change | Rufinamide (E2080) | Placebo |
|---|---|---|
| Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) | -24.20 (-93.5 to 27.2) | -3.25 (-81.6 to 151.9) |
50% Responder Rate in Tonic-Atonic Seizure Frequency was presented as the number of participants who achieved a 50% reduction in tonic-atonic seizure frequency.
| Participants | Rufinamide (E2080) | Placebo |
|---|---|---|
| Yes (50% Reduction Achieved) | 7 | 2 |
| No | 21 | 28 |
Percent change in the total seizure frequency (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\].
| Percent Change | Rufinamide (E2080) | Placebo |
|---|---|---|
| Percent Change in Total Seizure Frequency (Per 28 Days) | -32.90 (-87.3 to 15.4) | -3.05 (-52.2 to 133.0) |
Percent change in the frequency of seizures other than tonic-atonic seizures (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \[100 x (post-treatment value - baseline)/ baseline\]. Seizures analyzed other than tonic-atonic seizures included: Partial seizure freq. (frequency), Absence seizure, Atyp. (atypical) absence seizure, Myoclonic seizure, Clonic seizure, Tonic seizure, Tonic-clonic seizure, Atonic seizure, \& Uncla. (unclassified) epileptic seizure. The frequency of epileptic seizures was recorded in the diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner.
| Percent change | Rufinamide (E2080) | Placebo |
|---|---|---|
| Partial Seizure Freq. % Change (n=4,6) | -52.20 (-96.2 to -26.3) | 4.5 (-28.2 to 35.9) |
| Absence Seizure Freq. % Change (n=1,0) | 3.40 (3.4 to 3.4) | NA (NA to NA) |
| Atyp. Absence Seizure Freq. % Change (n=12,19) | -59.00 (-100.0 to 107.1) | -21.10 (-83.2 to 253.5) |
| Myoclonic Seizure Freq. % Change (n=10,10) | -52.35 (-100.0 to 53.3) | 6.60 (-46.1 to 270.0) |
| Clonic Seizure Freq. % Change (n=1,0) | -81.20 (-81.2 to -81.2) | NA (NA to NA) |
| Tonic Seizure Freq. % Change (n=28,28) | -24.20 (-92.6 to 42.8) | -3.60 (-83.8 to 274.8) |
| Tonic-clonic Seizure Freq. % Change (n=2,10) | -57.35 (-100.0 to -14.7) | 2.35 (-75.8 to 450.0) |
| Atonic Seizure Freq. % Change (n=10,12) | -63.10 (-100.0 to 68.8) | -6.10 (-100.0 to 2195.7) |
| Uncla. Epileptic Seizure Freq. % Change (n=1,0) | -88.70 (-88.7 to -88.7) | NA (NA to NA) |
CGIC in participants with Lennox-Gastaut Syndrome (LGS) relative to placebo was presented as number of participants in each category at the final assessment (last observation carried forward \[LOCF\]) \& at Week 12 of the Treatment Period. The investigator assessed the CGIC by comparing the participants' condition during the 4 weeks immediately before the completion (or discontinuation \[d/c\]) of the Treatment Period to his/her condition during the 4-week Observation Period (for participants who d/c'd the study during the Treatment Period, the CGIC was assessed by comparing the participant's condition from the start to discontinuation of the study treatment to his/her condition during the 4-week Observation Period). The CGIC was assessed according to the following 7-grade scale based on the frequency \& severity of seizures, AEs, and overall conditions of daily life. Markedly improved, Improved, Slightly improved, Unchanged, Slightly worsened, Worsened, Markedly worsened.
| participants | Rufinamide (E2080) | Placebo |
|---|---|---|
| Week 12: Markedly improved (n=25, 29) | 0 | 0 |
| Week 12: Improved (n=25, 29) | 9 | 0 |
| Week 12: Slightly Improved (n=25, 29) | 4 | 9 |
| Week 12: Unchanged (n=25, 29) | 10 | 18 |
| Week 12: Slightly Worsened (n=25, 29) | 1 | 1 |
| Week 12: Worsened (n=25, 29) | 1 | 1 |
| Week 12: Markedly Worsened (n=25, 29) | 0 | 0 |
| LOCF: Markedly Improved (n=28, 30) | 3 | 0 |
| LOCF: Improved (n=28, 30) | 9 | 0 |
| LOCF: Slightly Improved (n=28, 30) | 4 | 9 |
| LOCF: Unchanged (n=28, 30) | 10 | 19 |
| LOCF: Slightly Worsened (n=28, 30) | 1 | 1 |
| LOCF: Worsened (n=28, 30) | 1 | 1 |
| LOCF: Markedly Worsened (n=28, 30) | 0 | 0 |
Collected over From date of first dose until date of last dose of study treatment, up to approximately 1 year 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rufinamide (E2080) | — | 1/29 (3.4%) | 27/29 (93.1%) |
| Placebo | — | 1/30 (3.3%) | 21/30 (70%) |
| Event | Rufinamide (E2080) | Placebo |
|---|---|---|
| Drug EruptionSkin and subcutaneous tissue disorders | 1/29 | 1/30 |
| Event | Rufinamide (E2080) | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 9/29 | 9/30 |
| Status EpilepticusNervous system disorders | 8/29 | 5/30 |
| Decreased AppetiteMetabolism and nutrition disorders | 6/29 | 2/30 |
| SomnolenceNervous system disorders | 6/29 | 2/30 |
| VomitingGastrointestinal disorders | 5/29 | 1/30 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/29 | 4/30 |
| Dental CariesGastrointestinal disorders | 2/29 | 0/30 |
| NauseaGastrointestinal disorders | 2/29 | 0/30 |
| DehydrationMetabolism and nutrition disorders | 2/29 | 0/30 |
| GastroenteritisInfections and infestations | 0/29 | 2/30 |
One subject from the Rufinamide (E2080) group was excluded from the FAS because of the inappropriate diagnosis of the disease, dropping the total number from 29 to 28 participants.
| Age, Continuous(years) | Rufinamide (E2080) | Placebo | Total |
|---|---|---|---|
| Mean | 16.0 ± 7.1 | 13.9 ± 6.1 | 14.9 ± 6.6 |
| Sex: Female, Male(Participants) | Rufinamide (E2080) | Placebo | Total |
|---|---|---|---|
| Female | 11 | 11 | 22 |
| Male | 17 | 19 | 36 |
The record gives a start of Jun 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rufinamide